[go: up one dir, main page]

DK3592384T3 - Antistoffer, der specifikt binder til human il-1r7 - Google Patents

Antistoffer, der specifikt binder til human il-1r7

Info

Publication number
DK3592384T3
DK3592384T3 DK18711275.0T DK18711275T DK3592384T3 DK 3592384 T3 DK3592384 T3 DK 3592384T3 DK 18711275 T DK18711275 T DK 18711275T DK 3592384 T3 DK3592384 T3 DK 3592384T3
Authority
DK
Denmark
Prior art keywords
antibodies
human
specifically binding
binding
specifically
Prior art date
Application number
DK18711275.0T
Other languages
English (en)
Inventor
Karsten Beckmann
Stephan Fischer
Original Assignee
Mab Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mab Discovery Gmbh filed Critical Mab Discovery Gmbh
Application granted granted Critical
Publication of DK3592384T3 publication Critical patent/DK3592384T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK18711275.0T 2017-03-09 2018-03-09 Antistoffer, der specifikt binder til human il-1r7 DK3592384T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160191 2017-03-09
PCT/EP2018/055934 WO2018162724A1 (en) 2017-03-09 2018-03-09 Antibodies specifically binding to human il-1r7

Publications (1)

Publication Number Publication Date
DK3592384T3 true DK3592384T3 (da) 2025-09-15

Family

ID=58265918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18711275.0T DK3592384T3 (da) 2017-03-09 2018-03-09 Antistoffer, der specifikt binder til human il-1r7

Country Status (14)

Country Link
US (1) US11352432B2 (da)
EP (1) EP3592384B1 (da)
JP (1) JP7046089B2 (da)
CN (2) CN110382002B (da)
AU (1) AU2018232883B2 (da)
CA (1) CA3055256A1 (da)
DK (1) DK3592384T3 (da)
ES (1) ES3042097T3 (da)
FI (1) FI3592384T3 (da)
LT (1) LT3592384T (da)
PT (1) PT3592384T (da)
SI (1) SI3592384T1 (da)
WO (1) WO2018162724A1 (da)
ZA (1) ZA201905341B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021110873A1 (en) * 2019-12-04 2021-06-10 Medimmune Limited Antibodies against lif and uses thereof
WO2021127185A1 (en) * 2019-12-17 2021-06-24 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
EP4188430A4 (en) * 2020-07-28 2024-11-06 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
CN114276450B (zh) * 2020-09-27 2023-08-29 江苏荃信生物医药股份有限公司 抗人il-17a单克隆抗体及其用途
EP4228674A4 (en) * 2020-10-15 2025-01-29 Bioincept LLC SYSTEMS, COMPOSITIONS AND METHODS FOR DETERMINING THE VIABILITY OF EMBRYOS
US20240294633A1 (en) * 2021-06-04 2024-09-05 Nonagen Therapeutics Corporation Antibody specific for anti-bcl-6 antibody and methods of use
CN119095615A (zh) * 2022-01-11 2024-12-06 得克萨斯系统大学评议会 抗cd94抗体和嵌合抗原受体及其使用方法
EP4604988A1 (en) 2022-10-21 2025-08-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
CN115819580B (zh) * 2022-11-23 2023-09-05 武汉爱博泰克生物科技有限公司 针对人il-12的高亲和力兔单克隆抗体及其应用
CN115960236B (zh) * 2023-01-05 2024-08-06 江苏荃信生物医药股份有限公司 一种定量检测血清中抗人白介素4受体α单克隆抗体含量的酶联免疫分析方法
CN116355094B (zh) * 2023-02-21 2023-10-20 武汉爱博泰克生物科技有限公司 抗小鼠白介素12的单克隆抗体及制备方法
CN119569860B (zh) * 2023-09-07 2025-11-18 菲鹏生物股份有限公司 一种抗p24抗体及其应用
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
CN117603357B (zh) * 2023-11-29 2024-09-03 武汉爱博泰克生物科技有限公司 针对人孕激素受体的兔单克隆抗体及其应用
WO2025147472A1 (en) * 2024-01-02 2025-07-10 Phanes Therapeutics, Inc. Anti-611-ctf p95her2 antibodies and uses thereof
CN120860241A (zh) * 2024-04-29 2025-10-31 成都百利多特生物药业有限责任公司 抗人dll3抗体-喜树碱类药物偶联物及其医药用途
CN118240074A (zh) * 2024-04-30 2024-06-25 杭州旭科生物技术有限公司 抗艾滋病毒p24抗原的单克隆抗体及其应用和产品
CN118465262B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 一种测定细胞制剂中逆转录病毒载体残留的方法
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US8101179B2 (en) * 2005-03-31 2012-01-24 Biomedics Inc. Anti-CD20 monoclonal antibody
LT3018206T (lt) * 2005-12-01 2021-12-10 Nuevolution A/S Fermentiniai kodavimo būdai, skirti didelių bibliotekų efektyviai sintezei
CA2635445A1 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
WO2007117577A2 (en) 2006-04-07 2007-10-18 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-18 receptor
CN101946180B (zh) * 2007-12-19 2013-11-13 神谷来克斯公司 单分子检测用扫描分析器和使用方法
PT2307454T (pt) * 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o vegf
KR20180078345A (ko) * 2009-10-19 2018-07-09 테라노스, 인코포레이티드 통합형 건강 정보 취득 및 분석 시스템
US9255144B2 (en) 2010-12-20 2016-02-09 Medimmune Limited Anti-IL-18 antibodies and their uses
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
AU2014360678A1 (en) * 2013-12-06 2016-06-23 Fuwan Pty Ltd A method of treating neoplasia
WO2016199964A1 (ko) * 2015-06-10 2016-12-15 주식회사 이뮨메드 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편
HUE052869T2 (hu) * 2016-03-17 2021-05-28 Tillotts Pharma Ag TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
EP3241845A1 (en) * 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US20250002471A1 (en) * 2020-12-22 2025-01-02 Gilead Sciences, Inc. 6-substituted indole compounds
US20240059673A1 (en) * 2020-12-22 2024-02-22 Gilead Sciences, Inc. Substituted indole compounds

Also Published As

Publication number Publication date
CA3055256A1 (en) 2018-09-13
NZ756707A (en) 2024-07-05
EP3592384A1 (en) 2020-01-15
LT3592384T (lt) 2025-10-10
EP3592384B1 (en) 2025-07-02
ZA201905341B (en) 2021-10-27
JP2020510013A (ja) 2020-04-02
EP4623992A2 (en) 2025-10-01
FI3592384T3 (fi) 2025-09-29
ES3042097T3 (en) 2025-11-18
JP7046089B2 (ja) 2022-04-01
US11352432B2 (en) 2022-06-07
US20210130478A1 (en) 2021-05-06
SI3592384T1 (sl) 2025-11-28
CN110382002B (zh) 2025-08-15
PT3592384T (pt) 2025-10-01
WO2018162724A1 (en) 2018-09-13
AU2018232883B2 (en) 2024-10-17
CN120842411A (zh) 2025-10-28
CN110382002A (zh) 2019-10-25
AU2018232883A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
DK3592384T3 (da) Antistoffer, der specifikt binder til human il-1r7
DK3558369T3 (da) Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
IL276537A (en) Antibodies bind to GPRC5D
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL265321B1 (en) Cd3 binding antibodies
IL269531A (en) Improved antigen binding receptors
DK3350223T3 (da) Antistoffer, der binder specifikt til tl1a
DK3122781T3 (da) Bispecifikke antistoffer, der binder til cd38 og cd3
DK3606955T3 (da) Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
EP3471773A4 (en) ANTIBODIES BINDING CD3
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3328889T3 (da) Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
DK3110849T3 (da) Antistof, der binder erbb-2 og erbb-3
DK3328892T3 (da) Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
DK3097122T3 (da) Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
DK3242892T3 (da) Modificerede april-bindende antistoffer
SG11202100096XA (en) Antibodies binding to ilt4
DK2992100T3 (da) Agrokemiske sammensætninger omfattende antistoffer, der binder til sphingolipider
DK3665198T3 (da) Antistoffer, der binder egfr og cmet
DK3169706T3 (da) Antistoffer, der binder axl
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
DK2964258T3 (da) Antistoffer, der binder IL-23
IL272361A (en) Antibody binding active alpha-synuclein
IL269394A (en) Antibodies bind to STEAP-1